Emotions, as well as function, determine MD trust: study

Share this article:
Emotions, as well as function, determine MD trust: study
Emotions, as well as function, determine MD trust: study

Physician trust in pharmaceutical brands is driven by an emotional connection as well as functional attributes and perceptions of the manufacturer, said Harris Interactive, which found doctors gave Advair, Spiriva and Mirena top marks.

The firm queried physicians about branded drugs for asthma, COPD, osteoporosis, contraception and rheumatoid arthritis based on five measures of trust, including the product's familiarity, function and connection.

Joseph Vorassi, SVP healthcare research at Harris Interactive told MM&M that the components of each measurement break down as follows:  “For function, it's offering unique benefits, excellent outcomes and consistent results. On the connection, being able to identify with the product… On the rep side, it's being respectful of staff, being responsive, providing unbiased info.”

The most-trusted brands in the categories polled:

Asthma: Advair, followed by Symbicort

COPD: Spiriva, then Advair, Symbicort and Combivent

Osteoporosis:  Actonel, followed by Evista, Forteo, Prolia and Reclast

Contraception: Mirena, followed by NuvaRing, Lo LoEstrin and Depo-Provera

Rheumatoid Arthritis: Enbrel and Humira tied for first, followed by Remicade, Orencia and Rituxan
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?